Your browser doesn't support javascript.
Recent advances in antiviral effects of probiotics: potential mechanism study in prevention and treatment of SARS-CoV-2.
Montazeri-Najafabady, Nima; Kazemi, Kimia; Gholami, Ahmad.
  • Montazeri-Najafabady N; Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Kazemi K; Pharmaceutical Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Gholami A; Pharmaceutical Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Biologia (Bratisl) ; 77(11): 3211-3228, 2022.
Article in English | MEDLINE | ID: covidwho-1906510
ABSTRACT
SARS-CoV-2 is responsible for coronavirus disease 2019 (COVID-19), progressively extended worldwide countries on an epidemic scale. Along with all the drug treatments suggested to date, currently, there are no approved management protocols and treatment regimens for SARS-CoV-2. The unavailability of optimal medication and effective vaccines against SARS-CoV-2 indicates the requirement for alternative therapies. Probiotics are living organisms that deliberate beneficial effects on the host when used sufficiently and in adequate amounts, and fermented food is their rich source. Probiotics affect viruses by antiviral mechanisms and reduce diarrhea and respiratory tract infection. At this point, we comprehensively evaluated the antiviral effects of probiotics and their mechanism with a particular focus on SARS-CoV-2. In this review, we suggested the conceptual and potential mechanisms of probiotics by which they could exhibit antiviral properties against SARS-CoV-2, according to the previous evidence concerning the mechanism of antiviral effects of probiotics. This study reviewed recent studies that speculate about the role of probiotics in the prevention of the SARS-CoV-2-induced cytokine storm through the mechanisms such as induction of anti-inflammatory cytokines (IL-10), downregulation of pro-inflammatory cytokines (TNF-α, IL-2, IL-6), inhibition of JAK signaling pathway, and act as HDAC inhibitor. Also, the recent clinical trials and their outcome have been reviewed. Supplementary Information The online version contains supplementary material available at 10.1007/s11756-022-01147-y.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Traditional medicine / Vaccines Language: English Journal: Biologia (Bratisl) Year: 2022 Document Type: Article Affiliation country: S11756-022-01147-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Traditional medicine / Vaccines Language: English Journal: Biologia (Bratisl) Year: 2022 Document Type: Article Affiliation country: S11756-022-01147-y